Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study - PubMed
4 hours ago
- #immunotherapy
- #clinical trial
- #bladder cancer
- Study evaluates neoadjuvant sacituzumab govitecan plus pembrolizumab followed by adjuvant pembrolizumab in muscle-invasive bladder cancer (SURE-02).
- Standard treatment is radical cystectomy with neoadjuvant chemotherapy, but 50% of patients are ineligible or refuse it.
- Primary endpoint was clinical complete response rate (negative imaging and no viable tumor at re-TURBT).
- 39% of patients achieved clinical complete response, all metastasis-free, with two intravesical relapses.
- Grade 3 treatment-related adverse events occurred in 16% of patients, with no treatment-related deaths.
- Perioperative treatment showed promising results, allowing bladder preservation in ~40% of patients.
- Study funded by Merck Sharp & Dohme LLC and Gilead Sciences.